A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Inclusion Criteria:

- Men and non-pregnant women aged ≥18 years

- Hemoglobin A1c (HbA1c) ≥7.5% and ≤10.5%

- Type 2 diabetes on insulin or insulin + oral antihyperglycemic medication

- Participants with presumed diabetic kidney disease with or without hypertensive
nephrosclerosis diagnosed with moderate or severe CKD with estimated glomerular
filtration rate (eGFR) of ≥15 to <60 milliliters per minute (mL/min)/1.73 meter
squared (m^2)

- Able and willing to perform multiple daily injections

- Body mass index (BMI) between 23 and 45 kilogram/square meter (kg/m^2)

Exclusion Criteria:

- Stage 5 CKD as defined by eGFR <15 mL/min/1.73 m^2 OR having required dialysis

- Rapidly progressing renal dysfunction likely to require renal replacement

- History of a transplanted organ

- Type 1 diabetes mellitus

- At screening a systolic blood pressure of ≥150 mmHg or a diastolic blood pressure of
≥90 mmHg with or without antihypertensive medication

- An episode of ketoacidosis or hyperosmolar state/coma in the past 6 months or a
history of severe hypoglycemia in the past 3 months prior to the Screening Visit

- Cardiovascular conditions within 12 weeks prior to randomization: acute myocardial
infarction, New York Heart Association (NYHA) class III or class IV heart failure, or
cerebrovascular accident (stroke)

- Acute or chronic hepatitis

- Signs and symptoms of chronic or acute pancreatitis, or were in the past diagnosed
with pancreatitis

- Serum calcitonin ≥35 picograms per milliliter (pg/mL) at Screening Visit

- Self or family history of medullary C-cell hyperplasia, focal hyperplasia, or
carcinoma

- Known history of untreated proliferative retinopathy